Acute Myeloid Leukemia Clinical Trial
Official title:
A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
This is an international multicenter open label randomized phase III trial in children with relapsed and refractory acute myeloid leukemia (AML) such a disease. The main purpose of this study is to determine the efficacy and toxicity of liposomal daunorubicin when added to fludarabine, ara-C and G-CSF(FLAG) in children with relapsed and refractory AML.
Secondary objectives of this trial are:
- To determine the toxicity of liposomal daunorubicin when added to FLAG, in terms of
mucosal toxicity, bone marrow aplasia, short- and long-term cardiotoxicity and other
side effects as compared to patients treated with FLAG only.
- To determine the long-term clinical outcome prospectively in a large group of children
with refractory and relapsed acute myeloid leukemia.
- To determine the changes in minimal residual disease over time, and the prognostic
significance of minimal residual disease determined at various time-points.
- To determine the relation between in vitro cellular drug resistance and clinical and
cell biological features, minimal residual disease and clinical outcome in this patient
group
- To determine the pharmacokinetics of liposomal daunorubicin in relation to its toxicity
and efficacy
Reinduction treatment will be done with 2 courses of combination chemotherapy, with FLAG
(fludarabine, ara-C and G-CSF) in both courses as standard treatment. In the first course
there will be a randomisation for liposomal daunorubicin (DaunoXome®) to be added or not.
The second course should always concern FLAG. If patients have > 20% of blasts in the bone
marrow after the 1st course, or if they are not in complete remission (CR) after the 2nd
course, they will go off protocol. Patients in CR after reinduction treatment can
immediately proceed to stem cell transplantation. Consolidation chemotherapy should be given
if SCT is delayed. A 3rd course of intensive chemotherapy (VP16 and continuous infusion with
cytarabine) is the general recommendation. In selected patients, a low intensity
consolidation may be preferred, and such a schedule is described as well. The type of SCT is
based on the risk-group. Preferably, a matched sibling donor (MSD) SCT is performed. If a
MSD is not available all patients are candidates for a matched unrelated donor (MUD) SCT. If
a MUD is also not available, patients with primary refractory disease, early relapse (within
1 year from diagnosis), or greater than or equal to 2nd relapse, are candidates for the more
experimental haplo-identical donor (HID) SCT in view of the dismal prognosis. However,
patients with a late relapse (>1 year from initial diagnosis) have a better prognosis and
should be offered an autologous SCT if a MSD or MUD SCT is not possible. Only in case of
autologous SCT, maintenance treatment and/or adjuvant immunotherapy could be considered.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |